NCT02577432

Brief Summary

Background: Poor spinal anaesthesia block is common and is difficult to manage; so a technique to minimize its incidence is advisable. Hypotension is the commonest problem with spinal anesthesia. Multiple trials to prevent or combat hypotension using positional changes, fluid therapy and the use of vasopressors were tried. However, the drug choice and mode of administration as either bolus or infusion is still a matter of debate. Objectives: To compare the outcome of spinal injection of hyperbaric bupivacaine and fentanyl separately to standard injection of mixed fentanyl with hyperbaric bupivacaine. Design: A randomized, controlled clinical trial. Setting: Single medical center from 5/2013 to 10/2014. Patients \& Methods: 124 parturient scheduled for elective cesarean section (CS) were randomly allocated into two groups, each 62 parturient: Group M received spinal anesthesia using 10 mg bupivacaine 0.5% premixed with 25 µg fentanyl in the same syringe and Group S received 25 µg fentanyl in one syringe and 10 mg bupivacaine 0.5% without barbotage in a second syringe. Intravenous fluid co-load with 15 ml/kg warm lactated ringer solution was started as fast drip during, and continued after spinal anesthesia. Patients were monitored for hemodynamic parameters, time of sensory onset and height of maximum sensory block, lower limb motor blockade was scored using modified Bromage scale and the frequency of side effects.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
124

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2013

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

October 10, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 16, 2015

Completed
Last Updated

October 20, 2015

Status Verified

October 1, 2015

Enrollment Period

1.4 years

First QC Date

October 10, 2015

Last Update Submit

October 19, 2015

Conditions

Keywords

spinal anesthesia

Outcome Measures

Primary Outcomes (2)

  • Number of parturients needed more analgesics (unsatisfactory block) using Ochsner Health System.

    intraoperative

  • incidence of hypotension

    intraoperative

Study Arms (2)

(S) separate.

ACTIVE COMPARATOR

fentanyl and hyperbaric bupivacaine (sequentially)

Drug: fentanylDrug: Hyperbaric bupivacaine

(M) mixed

ACTIVE COMPARATOR

fentanyl and hyperbaric bupivacaine.(mixed)

Drug: fentanylDrug: hyperbaric bupivacaine

Interventions

Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.

(S) separate.

Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.

(S) separate.

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Parturient at full term.
  • Must be elective cesarean section.
  • Must be uncomplicated pregnancy

You may not qualify if:

  • Body weight \<50 kg or \>90 kg
  • Height ˂150 cm or \>170 cm.
  • Pre-eclampsia.
  • Any major systemic disease.
  • Contraindication to regional anesthesia.
  • Allergy to used medications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Fentanyl

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Amr A Keera, MD

    Dr. Benha Faculty of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

October 10, 2015

First Posted

October 16, 2015

Study Start

May 1, 2013

Primary Completion

October 1, 2014

Study Completion

October 1, 2014

Last Updated

October 20, 2015

Record last verified: 2015-10